Neurotech Release: Mente Autism Included On The Australian Register Of Therapeutic Goods
- Therapeutic Goods Administration (TGA) registers Mente Autism
- Registration and inclusion represents important milestone and opens access to Australian market
- Neurotech conducting German launch of Mente Autism at major autism congress
Perth, Australia & Malta – 5 June 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has received confirmation from the Therapeutic Goods Administration (TGA) that Mente Autism has been included on the Australian Register of Therapeutic Goods (ARTG).
Inclusion on the ARTG marks a significant milestone for the Company, enabling Neurotech to distribute and sell Mente Autism in Australia. Mente Autism is registered as a biofeedback system in the category Medical Device Class IIa.
Selection of a distribution partner for Mente Autism in Australia is underway and expected to be finalised in Q3 2017.
Wolfgang Storf, CEO of Neurotech, said: “This is another major milestone for our company. Inclusion on the ARTG enables us to legally supply Mente Autism in Australia and gives us access to a very large market with enormous potential. In line with our vision to improve the lives of people with neurological conditions, we can now help the many Australian families with children who are diagnosed with Autism Spectrum Disorder (ASD). These are exciting times for Neurotech and Mente Autism.”
GERMAN LAUNCH OF MENTE AUTISM AT 15th AUTISM CONGRESS, DORTMUND
Neurotech will be attending the 15th German Autism Congress in Dortmund, to be held 9 to 11 June. The Company will use the event to launch Mente Autism in the key market of Germany.
The congress brings together autism associations, medical professionals and suppliers under the theme of “Learning, Work, Life Quality”. It is a major event featuring thousands of visitors interested in all matters related to autism, providing a unique forum to present Mente Autism to specialists and parents alike.
Building on momentum post securing VDT Psychologie- & Medizinvertrieb as its first marketing and distributing partner in the region, this congress will serve as a high quality platform for Neurotech to engage with key stakeholders in Germany and build awareness of the Mente Autism device.
DR ADRIAN ATTARD TREVISAN TO PRESENT AT EUROPEAN NEUROCONVENTION
Neurotech’s founder, Dr Adrian Attard Trevisan, will be speaking on electroencephalogram (EEG) - driven therapies at the European NeuroConvention in London on 7 June.
Dr Attard Trevisan will deliver a keynote speech regarding real-time EEG driven therapies and how they are considered to be an easy, yet effective way forward in the world of ‘personalised stimulation’. He will also discuss the term ‘EEG slowing’ which derives from the ability to monitor and modulate slow brain wave activities, characterised by enhanced amplitudes of delta and theta waves over the other EEG frequencies and by a consistent alpha suppression. This relates to an EEG pattern found in a number of conditions including autism spectrum disorders, attention deficit disorder, depression and post-traumatic stress disorder.
The European NeuroConvention attracts visitors from leading businesses, health professions, research centres, associations and clinics as well as neuroscience experts from across the globe.
For more information about Neurotech and Mente Autism please visit: http://www.neurotechinternational.com. http://www.mentetech.com.
For more information please contact:
Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420
About Neurotech
Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: http://www.neurotechinternational.com
- Registration and inclusion represents important milestone and opens access to Australian market
- Neurotech conducting German launch of Mente Autism at major autism congress
Perth, Australia & Malta – 5 June 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has received confirmation from the Therapeutic Goods Administration (TGA) that Mente Autism has been included on the Australian Register of Therapeutic Goods (ARTG).
Inclusion on the ARTG marks a significant milestone for the Company, enabling Neurotech to distribute and sell Mente Autism in Australia. Mente Autism is registered as a biofeedback system in the category Medical Device Class IIa.
Selection of a distribution partner for Mente Autism in Australia is underway and expected to be finalised in Q3 2017.
Wolfgang Storf, CEO of Neurotech, said: “This is another major milestone for our company. Inclusion on the ARTG enables us to legally supply Mente Autism in Australia and gives us access to a very large market with enormous potential. In line with our vision to improve the lives of people with neurological conditions, we can now help the many Australian families with children who are diagnosed with Autism Spectrum Disorder (ASD). These are exciting times for Neurotech and Mente Autism.”
GERMAN LAUNCH OF MENTE AUTISM AT 15th AUTISM CONGRESS, DORTMUND
Neurotech will be attending the 15th German Autism Congress in Dortmund, to be held 9 to 11 June. The Company will use the event to launch Mente Autism in the key market of Germany.
The congress brings together autism associations, medical professionals and suppliers under the theme of “Learning, Work, Life Quality”. It is a major event featuring thousands of visitors interested in all matters related to autism, providing a unique forum to present Mente Autism to specialists and parents alike.
Building on momentum post securing VDT Psychologie- & Medizinvertrieb as its first marketing and distributing partner in the region, this congress will serve as a high quality platform for Neurotech to engage with key stakeholders in Germany and build awareness of the Mente Autism device.
DR ADRIAN ATTARD TREVISAN TO PRESENT AT EUROPEAN NEUROCONVENTION
Neurotech’s founder, Dr Adrian Attard Trevisan, will be speaking on electroencephalogram (EEG) - driven therapies at the European NeuroConvention in London on 7 June.
Dr Attard Trevisan will deliver a keynote speech regarding real-time EEG driven therapies and how they are considered to be an easy, yet effective way forward in the world of ‘personalised stimulation’. He will also discuss the term ‘EEG slowing’ which derives from the ability to monitor and modulate slow brain wave activities, characterised by enhanced amplitudes of delta and theta waves over the other EEG frequencies and by a consistent alpha suppression. This relates to an EEG pattern found in a number of conditions including autism spectrum disorders, attention deficit disorder, depression and post-traumatic stress disorder.
The European NeuroConvention attracts visitors from leading businesses, health professions, research centres, associations and clinics as well as neuroscience experts from across the globe.
For more information about Neurotech and Mente Autism please visit: http://www.neurotechinternational.com. http://www.mentetech.com.
For more information please contact:
Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420
About Neurotech
Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: http://www.neurotechinternational.com